# A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

> **NCT01240655** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** LCL161
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01240655
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240655, "A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01240655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*